Abstract INTerpath-001: phase 3 study of the mRNA-based individualized neoantigen therapy intismeran autogene plus pembrolizumab vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma Long GV, et al. Background: Many patients (pts) with resected high-risk MEL experience recurrence despite…9 Novembre 2026
Abstract STARBOARD phase 3: a randomized, double-blind study of first-line encorafenib, binimetinib, and pembrolizumab vs placebo and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma Schadendorf D, et al. Background: about half of patients (pts) with metastatic melanoma have BRAF…9 Novembre 2026
Abstract Primary analysis of HBI-8000-303: a randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma Khushalani NI, et al. Background: Outcome for patients with advanced melanoma has improved significantly with…9 Novembre 2026
Abstract Autologous tumor-infiltrating lymphocytes (GC101 TIL) in advanced melanoma: extended follow-up of a randomized, open-label, pivotal phase II trial Si L, et al. Background: GC101 is an autologous tumor-infiltrating lymphocyte (TIL) product that eliminates…7 Novembre 2026
Abstract Efficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: final results from IOV-COM-202 study Furness AJ, et al. Background: Despite advances in immune checkpoint inhibitor (ICI)-based therapy in front-line…7 Novembre 2026
Abstract Three-year distant metastasis-free survival of the phase 3 NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma Witteveen S, et al. Background: Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) followed by response-driven adjuvant treatment…7 Novembre 2026
Abstract Phase 1 dose expansion of a tetravalent CD137/PD-L1 bispecific antibody (FS222) in PD-1 inhibitor- resistant melanoma patients De Velasco G, et al. Background: FS222 is a PD-L1/CD137 bispecific antibody designed to promote…6 Novembre 2026
Abstract Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: primary analysis from HERTHENA-PanTumor01 McKean M, et al. Background: High human epidermal growth factor receptor 3 (HER3) expression is…6 Novembre 2026
Abstract Enfortumab vedotin plus pembrolizumab for refractory advanced melanoma: primary results from the PLUG-IN GEM 2301 trial De Velasco G, et al. Background: Melanoma has high NECTIN-4 expression levels. EV plus P,…6 Novembre 2026
Abstract Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy Davar D, et al. Background: Pts with advanced melanoma frequently experience progressive disease (PD) with limited…30 Ottobre 2026